Linking Epithelial-to-mesenchymal-transition and Epigenetic Modifications

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2012 Jun 19

PMID 22706095

Citations 18

Authors

Sonja C Stadler

C David Allis

Affiliations

Soon will be listed here.

Abstract

Cancer, as well as other human disorders, has long been considered to result from the consequence of genetic mutations in key regulatory genes that reside in pathways controlling proliferation, cellular differentiation, DNA damage and repair. In the case of cancer, mutations are well documented to arise in key oncogenes and critically important tumor-suppressor genes as part of the disease progression process. In addition to more accepted, genetic mutations, a rapidly increasing body of evidence supports the general view that profound alterations also occur in 'epigenes', whose products serve to define the 'epigenetic landscape' of tumor cells. Aberrant changes in epigenetic mechanisms such as DNA methylation, histone modifications and expression of micro RNAs play an important role in cancer and contribute to malignant transitions. Here we review recent studies linking epigenetic mechanisms to epithelial-to-mesenchymal transition as defined in normal processes, as well as abnormal transitions that lead to oncogensis.

Citing Articles

DPY30 promotes colorectal carcinoma metastasis by upregulating ZEB1 transcriptional expression.

Luo C, Su W, Jiang H, Luo L, Shen D, Su G Cancer Cell Int. 2023; 23(1):333.

PMID: 38115111 PMC: 10731791. DOI: 10.1186/s12935-023-03126-y.

Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis.

Dong Y, Hu H, Zhang X, Zhang Y, Sun X, Wang H Signal Transduct Target Ther. 2023; 8(1):95.

PMID: 36872368 PMC: 9986243. DOI: 10.1038/s41392-022-01302-6.

Epithelial-Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma.

Busuioc C, Ciocan-Cartita C, Braicu C, Zanoaga O, Raduly L, Trif M J Pers Med. 2021; 11(6).

PMID: 34073426 PMC: 8229043. DOI: 10.3390/jpm11060476.

Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.

Yu H, Zhang D, Lian M CNS Neurosci Ther. 2021; 27(4):470-483.

PMID: 33459509 PMC: 7941239. DOI: 10.1111/cns.13587.

Fine-tuning the metabolic rewiring and adaptation of translational machinery during an epithelial-mesenchymal transition in breast cancer cells.

Fernandez-Calero T, Davyt M, Perelmuter K, Chalar C, Bampi G, Persson H Cancer Metab. 2020; 8:8.

PMID: 32699630 PMC: 7368990. DOI: 10.1186/s40170-020-00216-7.

References

Wang G, Allis C, Chi P . Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med. 2007; 13(9):363-72. DOI: 10.1016/j.molmed.2007.07.003. View

Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, Li E . Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature. 2004; 429(6994):900-3. DOI: 10.1038/nature02633. View

Varambally S, Cao Q, Mani R, Shankar S, Wang X, Ateeq B . Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908):1695-9. PMC: 2684823. DOI: 10.1126/science.1165395. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Lapidus R, Nass S, Davidson N . The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia. 2000; 3(1):85-94. DOI: 10.1023/a:1018778403001. View

Saito Y, Jones P . Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006; 5(19):2220-2. DOI: 10.4161/cc.5.19.3340. View

Drane P, Ouararhni K, Depaux A, Shuaib M, Hamiche A . The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010; 24(12):1253-65. PMC: 2885661. DOI: 10.1101/gad.566910. View

10.

Thomson J, Newman M, Parker J, Morin-Kensicki E, Wright T, Hammond S . Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006; 20(16):2202-7. PMC: 1553203. DOI: 10.1101/gad.1444406. View

11.

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

12.

Schwartz B, Hofer M, Lemieux M, Bauer D, Cameron M, West N . Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011; 71(7):2686-96. PMC: 3070805. DOI: 10.1158/0008-5472.CAN-10-3513. View

13.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

14.

Friedman J, Jones P, Liang G . The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 2009; 8(15):2313-4. PMC: 2846299. DOI: 10.4161/cc.8.15.9168. View

15.

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti G, Papotti M . Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010; 8(9):1207-16. DOI: 10.1158/1541-7786.MCR-10-0052. View

16.

Belinsky S, Klinge D, Stidley C, Issa J, Herman J, March T . Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003; 63(21):7089-93. View

17.

Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P . The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008; 111(10):5093-100. PMC: 2384136. DOI: 10.1182/blood-2007-10-117762. View

18.

Filipowicz W, Jaskiewicz L, Kolb F, Pillai R . Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005; 15(3):331-41. DOI: 10.1016/j.sbi.2005.05.006. View

19.

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

20.

Lin T, Ponn A, Hu X, Law B, Lu J . Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene. 2010; 29(35):4896-904. PMC: 3093107. DOI: 10.1038/onc.2010.234. View